New drug cocktail aims to stop transplant rejection

NCT ID NCT03945591

Completed Prevention Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested whether giving high doses of cyclophosphamide and bortezomib after a stem cell transplant could prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Twenty-three adults with blood cancers received the drug combination. The main goals were to see how many developed acute or chronic GVHD. The study is complete, but results are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclophosphamide and bortezomib
What this could lead to: If successful, this drug combination could become a standard way to prevent graft-versus-host disease after stem cell transplants, making the procedure safer.
What could go wrong: This is a small, early-phase trial with only 23 participants and no comparison group. The results may not apply to all patients, and the drugs can cause side effects like infections or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GVHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GVHD

Contacts and locations

Locations

New York University School of Medicine

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.